Close Menu

NEW YORK (GenomeWeb) – Tangen Biosciences today announced that it has closed a $9 million Series A equity financing round and will use the proceeds to develop its TangenDx platform for two undisclosed infectious disease tests performed in the clinic.

Tangen said that its platform employs rapid isothermal nucleic acid detection of targeted DNAs and RNAs directly from specimens. The platform may enable use of low cost, portable, and rapid MDx diagnostic capabilities outside traditional laboratories, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.